A randomised, parallel-group, double-blind, placebo-controlled study of DPK-060 to investigate clinical safety and efficacy in patients with acute external otitis
Latest Information Update: 05 May 2013
At a glance
- Drugs DPK 060 (Primary)
- Indications Otitis externa
- Focus Adverse reactions
- Sponsors DermaGen
- 21 Dec 2012 Status changed from recruiting to completed based on information reported in a Pergamum AB media release.
- 21 Dec 2012 The primary endpoint of drug safety and tolerability was met according to a Pergamum AB media release.
- 03 Apr 2012 New trial record